l e t t e r s l e t t e r s disorder associated with the development of lupus also showing an upregulation of type I interferon activity [19] [20] [21] . Our findings reveal a previously unrecognized link between TRAP activity and interferon metabolism and further emphasize the importance of the type I interferon response in autoimmunity.
l e t t e r s
We studied ten individuals from eight families showing features consistent with the immuno-osseous dysplasia spondyloenchondrodysplasia. Of particular note was the diverse spectrum of autoimmune phenotypes observed in these individuals (cases), including systemic lupus erythematosus, Sjögren's syndrome, hemolytic anemia, thrombocytopenia, hypothyroidism, inflammatory myositis, Raynaud's disease and vitiligo. Haplotype data indicated the disease gene to be on chromosome 19p13, and linkage analysis yielded a combined multipoint log 10 odds (LOD) score of 3.6. Sequencing of ACP5, encoding tartrate-resistant acid phosphatase, identified biallelic mutations in each of the cases studied, and in vivo testing confirmed a loss of expressed protein. All eight cases assayed showed elevated serum interferon alpha activity, and gene expression profiling in whole blood defined a type I interferon signature. Our findings reveal a previously unrecognized link between tartrate-resistant acid phosphatase activity and interferon metabolism and highlight the importance of type I interferon in the genesis of autoimmunity.
We initially ascertained three individuals showing a wide range of autoimmunity in association with intracranial calcification and spasticity. We considered the immuno-osseous dysplasia spondyloenchondrodysplasia (SPENCD, MIM271550) as a differential diagnosis in these cases. Although the disorder is regarded primarily as a skeletal dysplasia 1 , individuals with SPENCD have been reported to show immune dysfunction and neurological involvement 2, 3 . Radiological investigations in our cases revealed the characteristic metaphyseal and vertebral bone lesions described in SPENCD. We therefore sought to determine the genetic basis of this phenotype.
The demographic characteristics and clinical features of a total of ten cases with SPENCD are summarized in Table 1 , Figure 1 and Supplementary Table 1 . Four cases fulfilled the American College of Rheumatology classification criteria for a diagnosis of systemic lupus erythematosus (SLE) 4 . These criteria included elevated anti-nuclear antibodies, double stranded DNA (dsDNA) antibodies, thrombocytopenia and nephritis or non-erosive arthritis. Additionally, case 1 showed overlapping features of systemic sclerosis, Sjögren's syndrome and an inflammatory myositis. Three further cases exhibited Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature elevated dsDNA antibody and nuclear antibody titers. Possibly related to immune activation, four of the six cases assessed showed intracranial calcification, a recognized feature of neurolupus 5 .
A genome-wide genotyping analysis in three unrelated cases born to consanguineous parents determined an overlapping region of homozygosity on chromosome 19p13 (Fig. 2) . Linkage analysis gave a maximum multipoint LOD score of 3.6 between base-pair positions 10,527,380 and 13,214,722. This region contained a total of 95 RefSeq annotated genes. Genotyping of case 1 demonstrated two contiguous markers, one copy number probe (CN_784690) and one SNP (rs2071484) that failed to hybridize, indicating a possible homozygous deletion within ACP5. DNA from this case was refractory to PCR amplification of all exons of ACP5 despite good amplification of non-ACP5 PCR products and good amplification of DNA from the single available parent and from control DNA. Further evidence of a homozygous deletion in this case came from quantitative multiplex PCR of short fluorescent fragments (QMPSF) of DNA from the affected individual and her mother and from reverse transcription PCR analysis ( Supplementary  Fig. 1) . We were not able to define the precise breakpoints of the deletion by PCR. Although the parents of case 1 were not knowingly consanguineous, genotype data demonstrated a run of 35 homozygous SNPs in a 270-kb segment between rs4804628 and rs318699 encompassing ACP5, possibly suggesting distant shared ancestry.
Sequencing of the complete coding region of ACP5 revealed mutations in the further nine cases tested ( Table 1) . All mutations segregated with the disease in the families investigated, and all parents tested were heterozygous for a relevant familial mutation. All missense mutations were in highly conserved residues from a representative sample of eukaryotic species containing tartrate-resistant acid phosphatase (TRAP) ( Supplementary Fig. 2) . None of the mutations identified were present on 210 alleles from control samples of mixed ethnicity.
The observation of biallelic null mutations in four out of the eight families studied indicated that the SPENCD phenotype results from a loss of TRAP activity. To explore this possibility further, we measured levels of total TRAP protein and its 5a isoform in plasma from six cases. Compared to five age-matched controls and an unaffected sibling of subjects 2 and 3 who was homozygous for the wildtype allele as determined by gene sequencing, levels of total TRAP protein were negligible and TRAP 5a protein was undetectable, indicating an almost complete lack of TRAP synthesis or secretion in the affected cases tested ( Fig. 3) . It is of note that cases 4 and 9 were homozygous for missense mutations and that cases 2 and 3 carried a missense alteration on one allele, suggesting that these missense changes also act as null mutations, perhaps through protein misfolding and the l e t t e r s induction of protein degradation. This hypothesis is supported by bioinformatic assessment of the protein structure, in which all four missense changes are predicted to result in substantial protein destabilization ( Fig. 4) .
Although Acp5-null mice show a skeletal dysplasia highly reminiscent of the human disease SPENCD 6 , they do not develop an overt autoimmune phenotype. However, these mice do show disordered macrophage pro-inflammatory cytokine production 7 . Considering both the importance of cytokine interferon alpha in the pathogenesis of the prototypic autoimmune disorder SLE 8 and the clinical overlap with the Mendelian interferon-opathy Aicardi-Goutières syndrome 3, 9 , we sought to assess type I interferon activation in individuals affected with SPENCD. Notably, type I interferon activity was elevated in serum from all eight subjects sampled ( Fig. 3) , with a persistent elevation present in five cases with two or more recorded measurements. This activity was completely abolished with anti-sera against interferon alpha but not with anti-sera against interferon beta (Supplementary Table 2 ).
Individuals with SLE frequently show an increased expression of type I interferon-stimulated genes, a so-called interferon signature 10 . To determine if a similar signature was present in individuals with SPENCD, we undertook genome-wide microarray analysis in three affected subjects. This analysis identified 18 genes that were greater than fourfold overexpressed in whole blood from cases compared to age-matched controls (Fig. 5a, Supplementary Fig. 3 and Supplementary Table 3 ), 15 of which are recognized as interferonstimulated genes. These data were confirmed by quantitative PCR (qPCR) analysis in five cases. We did not find evidence of a circulating inducer of interferon activity in sera from cases ( Supplementary  Table 4 ), possibly suggesting an upregulation of type I interferon through a cell-intrinsic mechanism.
The above data demonstrate that loss of TRAP protein results in a dramatic upregulation of interferon alpha and type I interferonstimulated genes in individuals affected with SPENCD. In marked contrast, we found normal levels of interferon gamma protein ( Supplementary Table 5 ) and IL-10 and IL-12 RNA in whole blood from cases (Fig. 5b) . Moreover, we saw normal numbers of T and B cells, including T regulatory cell subsets, in two cases, cases 4 and 6 (data not shown), suggesting that the autoimmune predisposition in TRAP deficiency is not related to a quantitative Figure 2 Summary of mutation data. (a) The AutoSNPa output for Chromosome 19p generated from genome-wide SNP analysis of five unrelated individuals (C denotes case). We identified a shared region of homozygosity (indicated by the red box) in three cases (4, 6 and 7) born to consanguineous parents between base-pair positions 10,527,380 and 13,214,722 (black and yellow bars indicate homozygous and heterozygous SNPs, respectively). Within this homozygous region, case 1 showed a failure of hybridization for a copy number probe and an adjacent SNP probe. (b) We performed quantitative multiplex PCR of short fluorescent fragments to confirm the presence of the putative deletion in this case. Representative data from an analysis of exons 4 and 6 indicates that no products were seen using DNA from the proband (with a predicted copy number of 0), consistent with a homozygous ACP5 deletion, whereas her mother carries a heterozygous deletion as expected (with a predicted copy number of 1, compared to a predicted copy number of 2 in the control). DNA from the father was unavailable. Interferon alpha (IU/ml) Figure 3 Levels of TRAP protein and interferon alpha activity in cases with mutations in ACP5. (a) We used monoclonal antibodies to measure levels of total TRAP protein and TRAP isoform 5a in plasma from six cases with ACP5 mutations and compared them with levels in age and sex-matched control samples. We also tested an unaffected sibling of cases 2 and 3 who was homozygous for the wildtype allele on gene sequencing (designated control 001). All six cases demonstrated only background levels of total protein and an absence of 5a protein. (b) We obtained serum samples from eight cases with mutations in ACP5, and we measured interferon alpha levels using a biological assay of antiviral activity. Five cases were assayed serially, with greater than one month intervals between assay points. On only one occasion was the level of interferon alpha within the normal range (<2 IU/ml) in any of the cases sampled. 1 3 0 VOLUME 43 | NUMBER 2 | FEBRUARY 2011 Nature GeNetics l e t t e r s defect of regulatory T cells. These data indicate a primary role for TRAP in innate immunity, a contention further supported by the observation that TRAP is induced by lipopolysaccharide 11 and by nucleic acid ligands in a sequence non-specific and non-TLR9dependent manner 12 . Osteopontin, encoded by OPN, is a recognized substrate for osteoclast-derived TRAP in vivo 13 . Interestingly, polymorphisms in OPN and serum osteopontin levels show an association with interferon alpha levels in individuals with lupus 14 , possibly through an involvement of osteopontin in the regulation of interferon alpha production by plasmacytoid dendritic cells (pDCs) 15 , a major source of type I interferon. For these reasons, we assayed total osteopontin in serum from cases but did not see a statistically significant difference between cases and controls (Supplementary Fig. 4 ). Furthermore, although we observed fold-levels of ACP5 expression in pDCs equivalent to those in peripheral blood mononuclear cells, we saw much higher levels in macrophages and non-plasmacytoid dendritic cells ( Supplementary Table 6 ). Of note, ACP5 mRNA expression by human pDCs (Supplementary Table 7) , as well as by mouse macrophage and mouse dendritic cells (data not shown), was not increased following interferon alpha stimulation, perhaps indicating that TRAP does not act in a simple feedback regulatory loop within these cells. However, the possibility remains that loss of TRAP activity causes an increase in phosphorylated intracellular osteopontin 16 in pDCs or other relevant cell types, leading to an increase in circulating interferon alpha through an as yet undefined pathway.
Individuals with SPENCD show a truly remarkable spectrum of autoimmunity. In relation to SLE, together with deficiency of early components of the classical complement pathway 17 Computational analysis of missense mutations in the context of protein structure. We modeled each of the four missense mutations in the context of the crystal structure 22 . Interactions between the mutated side chains and the rest of the protein are indicated; pink and yellow spikes indicate destabilizing van der Waals overlaps and green lenses represent stabilizing hydrogen bonds. Van der Waals contacts are omitted for clarity. The least destabilizing side chain conformation ('rotamer') is shown in each case. Insets illustrate the wildtype residues and their interactions with the rest of the protein shown from the same viewpoint. For each alteration, van der Waals overlaps are large enough that they are likely to substantially destabilize the structure. In addition, in c, there is loss of a hydrogen bond that is stabilizing in the wildtype, and in d, the charged NH3 group of the lysine is buried from solvent and not able to make a neutralizing charge-charge interaction, further destabilizing the mutant structure. Figure 5 Gene expression analysis in cases with TRAP deficiency. (a) We undertook whole-transcriptome microarray expression analysis in three cases and compared the results to the data derived from three age-matched control samples. We identified a subset of 18 genes that were fourfold or more upregulated in cases, with a significance level for the comparisons of P < 0.0005 and a false discovery value of <0.2 (supplementary Fig. 3) . Fifteen of these genes are known to be interferon stimulated, characteristic of a type I interferon signature. The intensity plot was generated from the gene expression values (log 2) that had been standardized (for each gene, the mean was set to zero and the standard deviation was set to 1) using Partek Genomics Solution (version 6.5, Partek Inc.). (b) qPCR data for a representative sample of these upregulated genes: LY6E, MX1, USP18, RSAD2, OAS1, IFI44L, IL-10 and IL-12. All genes assessed in the case group were significantly upregulated (P < 0.001) compared to controls, except for IL-10 and IL-12, confirming the type 1 interferon signature seen on microarray analysis and showing an absence of up-or down-regulation of IL-10 and IL-12. RQ is equal to 2 −∆∆Ct , with ∆∆Ct ± standard deviations, that is the normalized fold change relative to a calibrator.
